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SUMMARY 
 
FLT3 is a receptor tyrosine kinase that appears to play a significant role in 
leukaemogenesis. Activating mutations of FLT3 are present in approximately one-
third of AML patients and are associated with adverse clinical outcome, while many 
non-mutated cases also show evidence of FLT3 activation. FLT3 thus represents a 
potentially-exciting molecular therapeutic target. A number of small-molecule 
tyrosine kinase inhibitors with anti-FLT3 activity have been developed and several of 
these compounds have entered early phase clinical trials where clinical anti-leukaemic 
activity has been demonstrated. The depth and duration of clinical responses to FLT3 
inhibitor monotherapy have been modest, however, and a number of mechanisms by 
which blasts may acquire resistance have been proposed. Based on pre-clinical 
evidence of synergy with conventional chemotherapy, several combination trials are 
now underway. FLT3 inhibition may also be effective used in combination with other 
molecularly-targeted agents, in post-chemotherapy stem-cell-directed maintenance 
therapy and in MLL-rearranged infant ALL. 
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INTRODUCTION 
 
Although gradual improvements in combination chemotherapy regimens and 
supportive care strategies have achieved a significant rise in cure rates in acute 
myeloid leukaemia (AML) over the last thirty years, the majority of patients continue 
to die from their disease. Only 35-45% of patients below the age of 60 years will be 
long-term survivors, and this figure falls to less than 15% in older patients 
(Lowenberg et al, 1999). Treatment with conventional cytotoxic agents may have 
reached its limits. Advances in the understanding of the heterogeneous molecular 
pathogenetic mechanisms underlying AML suggest that novel agents targeting 
individual molecular lesions, used either alone, in combination, or as an adjunct to 
conventional chemotherapy, hold much promise for further clinical improvement, 
with the drive toward such a targeted therapeutic approach being fuelled by the 
overwhelming success of the tyrosine kinase inhibitor imatinib mesylate in chronic 
myeloid leukaemia (CML)(Sawyers, 2002). The important role played by FMS-like 
tyrosine kinase 3 (FLT3) in the survival and proliferation of AML blasts, and its 
mutation and overexpression in large numbers of AML patients, make FLT3 a 
particularly attractive target. This review discusses the pre-clinical and early clinical 
development of small molecule inhibitors of FLT3 along with the ongoing 
translational research that will help to define their future clinical roles. Although some 
discussion of the biology of the FLT3 receptor itself is necessary, an extensive review 
of the structure, molecular function and signalling of FLT3 is beyond the scope of this 
article and the reader is referred to previous excellent reviews in this and other 
journals (Kottaridis et al, 2003;Levis & Small, 2003a;Stirewalt & Radich, 
2003;Gilliland & Griffin, 2002). 
 
 
THE FLT3 RECEPTOR – NORMAL BIOLOGY AND FUNCTION 
 
FLT3, also known as fetal liver kinase-2 (FLK-2) or stem cell kinase 1 (STK-1), is 
encoded by a 24-exon gene located on chromosome 13q12 (Rosnet et al, 1993;Small 
et al, 1994). It shares the same structural features as other members of the type III 
receptor tyrosine kinase family such as FMS, KIT and PDGFRα and β, namely an 
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extracellular ligand-binding region with 5 immunoglobulin-like domains, a cell 
membrane-spanning domain, and a cytoplasmic portion comprising a juxtamembrane 
region and split tyrosine kinase motifs. FLT3 is expressed on early haematopoietic 
progenitor cells with expression normally being lost as differentiation occurs (Gotze 
et al, 1998). The ligand for FLT3 (FLT3 ligand or FL) is expressed by virtually all 
cell types and appears to act in synergy with other cytokines in promoting 
haematopoietic expansion (Rusten et al, 1996). Upon stimulation with FL, FLT3 
dimerises and undergoes autophosphorylation, upregulating its tyrosine kinase 
activity and triggering signalling through an array of downstream pathways that 
promote cell proliferation and inhibit apoptosis including PI-3 kinase/AKT and 
RAS/MAPK and STAT5 (Lavagna-Sevenier et al, 1998;Marchetto et al, 1999). 
Targeted disruption of FLT3 or FL in murine gene knockout models results in viable 
mice with subtly reduced numbers of haematopoietic progenitors, particularly of B-
lymphoid lineage (McKenna et al, 2000). 
 
 
FLT3 IN ACUTE LEUKAEMIA 
 
The FLT3 receptor is expressed at high levels in 70-100% of cases of AML and 
virtually all cases of B-lineage acute lymphoblastic leukaemia (ALL) (Rosnet et al, 
1996;Birg et al, 1992;Carow et al, 1996). FLT3 emerged as a potential therapeutic 
target largely following the discovery of activating mutations of FLT3 that occur in 
approximately one-third of AML patients and fall into two main classes. Internal 
tandem duplications (FLT3-ITDs), first described by Nakao and colleagues in 1996, 
consist of in-frame duplications of variable lengths of the juxtamembrane domain-
encoding sequence of exons 14 and 15 (Nakao et al, 1996). Pooled data from over 
5,000 AML patients show an overall FLT3-ITD incidence of 23% in newly diagnosed 
patients, with a lower incidence in children (Levis & Small, 2003a). ITDs are 
associated with leucocytosis at presentation and, with the exception of acute 
promyelocytic leukaemia (APL) where they occur commonly, are seen predominantly 
in normal karyotype AML. It is now well documented that FLT3-ITD mutations are 
associated with poor prognosis, in terms of increased relapse rate and reduced overall 
survival (Kottaridis et al, 2001;Meshinchi et al, 2001). Patients with a high mutant-to-
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wild type FLT3 allelic ratio have a particularly dismal outlook (Whitman et al, 
2001;Thiede et al, 2002) and ITD size may also have prognostic significance 
(Stirewalt et al, 2006). A further 8-12% of AML patients have single base 
substitutions, small deletions or insertions in the activation loop of the tyrosine kinase 
domain (FLT3-TKDs), most frequently involving substitution of aspartic acid 835 
with tyrosine (D835Y) (Yamamoto et al, 2001). FLT3-TKD mutations do not appear 
to have the same adverse prognostic implications as FLT3-ITDs although complete 
consensus has not yet been reached on this issue and a favourable prognostic 
association has even been proposed (Mead et al, 2005).  
 
Both types of FLT3 mutation result in constitutive activation of the receptor in the 
absence of ligand, FLT3-ITDs through interference with the negative regulatory 
function of the juxtamembrane domain (Griffith et al, 2004), and FLT3-TKDs 
probably through stabilisation of the activation loop in the open ATP-binding 
configuration. Mutations of FLT3 are examples of so-called ‘class II’ leukaemic 
mutations, increasing cell proliferation and survival but, unlike class I mutations, not 
effecting haematopoietic differentiation (Gilliland & Griffin, 2002): FLT3-ITDs 
induce a fatal myeloproliferative disease-like phenotype in mouse bone marrow 
transplant models, but are not sufficient to cause overt AML (Kelly et al, 2002b). 
When FLT3-ITD mutations are combined with other genetic alterations, however, 
transformation to leukaemia does occur: in experiments with promyelocytic 
leukaemia-retinoic acid receptor α (PML-RARα) transgenic bone marrow, FLT3-ITD 
strongly increases the penetrance and decreases the latency period for the 
development of APL (Kelly et al, 2002a). FLT3-TKD mutations, although also 
associated with activation of the FLT3 receptor appear to have subtly different 
biological consequences to ITDs, causing less activation of signal transducer and 
activation of transcription (STAT) proteins (Choudhary et al, 2005) and inducing 
an oligoclonal lymphoproliferative rather than myeloproliferative phenotype in a 
murine bone marrow transplant model (Grundler et al, 2005).   
 
The large body of data that has now been assembled regarding the incidence and 
prognostic impact of FLT3 mutations, has established the ITD-mutated FLT3 
receptor as a worthwhile potential therapeutic target, although the rationale for 
targeting TKD-mutated FLT3 remains less clear. Whether overexpressed non-
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mutated wild-type (WT) FLT3 plays a significant role in the pathogenesis of AML 
and should also be targeted remains a matter of debate. Leukaemic blasts frequently 
co-express FLT3 and FL, creating autocrine and paracrine signalling loops that cause 
constitutive activation of WT FLT3 (Zheng et al, 2004;Drexler, 1996) and there is 
evidence from murine models that constitutively activated WT FLT3 can contribute to 
leukaemogenesis: lethally irradiated mice transplanted with WT FLT3-expressing 
stem cells retrovirally transduced to coexpress FL develop either myeloid or lymphoid 
leukaemia after a long lag period (Hawley et al, 1998). While the question of the role 
of WT FLT3 remains open, there remains scientific rationale for the inclusion of both 
mutated and WT FLT3 in the laboratory assessment and early clinical study of FLT3-
selective tyrosine kinase inhibitors. 
  
 
FLT3 INHIBITORS IN AML 
 
The successes of imatinib mesylate (Glivec) in CML and transtuzimab (Herceptin) in 
breast cancer have provided a tangible glimpse of the clinical gains that may be 
achievable through targeting dysregulated tyrosine kinase activity in cancer. Imatinib 
mesylate monotherapy induces haematological and cytogenetic remissions in the 
majority of patients with chronic phase CML (Kantarjian et al, 2002). In AML, 
however, FLT3 is only one among several genetic ‘hits’ that combine to cause the 
disease; more analogous to BCR/ABL in CML blast crisis / Philadelphia positive 
ALL, or HER2, a member of the ErbB receptor tyrosine kinase family that is 
overexpressed in 20-30% of breast cancer patients. In these situations imatinib and 
transtuzimab, a monoclonal antibody directed against HER2, produce favourable 
clinical responses, but not outright cures (Druker et al, 2001;Hortobagyi, 2001).  
 
Large drug discovery programmes in the pharmaceutical industry have identified a 
range of potential small molecule tyrosine kinase inhibitors with varying degrees of 
specificity towards FLT3. Candidate compounds tend to initially move through a 
well-established series of in vitro laboratory investigations (Levis & Small, 2003b). 
FLT3-inhibitory activity is determined either through in vitro kinase assays which 
involve purifying FLT3 and then testing the ability of the inhibitor to prevent FLT3-
mediated phosphorylation of a defined substrate such as a peptide-coated ELISA well, 
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or, perhaps more meaningfully, by cell-based phosphorylation assays in which intact 
FLT3-expressing cells are exposed to the inhibitor, followed by lysis, 
immunoprecipitation and immunoblotting with anti-phosphotyrosine antibodies. The 
relationship between FLT3-inhibition and the ability of an agent to induce 
cytotoxicity is then assessed by incubating FLT3-expressing cell lines or primary 
patient samples with a range of concentrations of the compound before measuring cell 
viability using techniques such as MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulphophenyl]-2H-tetrazolium) assay or assessment of 
annexin V binding. Murine models of FLT3-dependent leukaemia may be used to 
demonstrate prolongation of survival in animals treated with the inhibitor, with 
successful compounds moving forward to animal toxicity studies and early phase 
human trials. Most candidate FLT3-inhibitory molecules are hydrophobic and highly 
protein-bound: only the minority of drug that remains free in the plasma is expected to 
show clinical activity and this limits direct extrapolation of results obtained during in 
vitro studies performed in aqueous culture medium into the clinical setting. Once a 
promising agent has entered the clinic, adjunctive laboratory studies are essential to 
allow correlation of patient response with the degree and duration of in vivo FLT3 
inhibition achieved.  
 
 
INDIRECT INHIBITORS OF FLT3 – HSP-90 INHIBITORS 
 
Inhibitors of the molecular chaperone Heat shock protein 90 (Hsp-90) were the first 
class of compounds described to have inhibitory effects on FLT3 (Figure 1). 
Herbimycin A, a naturally occurring product of Streptomyces sp. was found to both 
inhibit the in vitro growth of FLT3-ITD transformed cells and reduce tumour size in a 
FLT3-ITD-driven mouse tumour model (Zhao et al, 2000). FLT3-ITD appears to 
require Hsp-90 for proper folding and stabilisation: the anti-FLT3 effect of 
herbimycin A occurs indirectly through dissociation of the complex formed between 
FLT3-ITD and Hsp-90. WT FLT3 does not associate with Hsp-90 and is thus not 
affected by Herbimycin A (Minami et al, 2002). Another Hsp-90 inhibitor, the 
geldanamycin analogue 17-N-allylamino-17-demethoxyl geldanamycin (17-AAG) 
has shown promising in vitro activity against FLT3-ITD AML (George et al, 2004). 
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No reports regarding the clinical development of these compounds have yet been 
published. 
 
 
DIRECT FLT3 INHIBITORS 
 
Although the other small molecules that are currently in development as FLT3 
inhibitors belong to a variety of chemical classes (Table 1) they are all heterocyclic 
compounds that directly inhibit FLT3 by mimicking the purine ring structure of 
adenosine and thus competing with ATP for binding to the ATP-binding pocket of the 
kinase domain of the FLT3 receptor. These agents may bind to the active, inactive or 
transitional state of FLT3, with their selectivity being greatly influenced by changes 
in the tertiary structure of the binding pocket that result from single amino acid 
changes such as those caused by FLT3-TKD mutations (Grundler et al, 2003;Clark et 
al, 2004). The pre-clinical and clinical development of each class of compound will 
be discussed in turn. An overview of the current published clinical trial literature is 
given in Table 2. 
 
Quinoxalines 
The first direct FLT3 inhibitors to be described were the bicyclic quinoxalines 
AG1295 and AG1296 (Figure 2) which were both originally described as PDGF-R 
inhibitors but subsequently found to inhibit FLT3-ITD and WT FLT3 (but not FLT3-
TKD) with a 50% inhibitory concentration (IC50) of approximately 300nM. Due to 
their hydrophobicity, low bioavailability and relatively low potency these compounds 
are useful only as research tools but provided important validation of FLT3 as a 
therapeutic target. AG1295 was found to be selectively cytotoxic to primary AML 
blasts harbouring FLT3 mutations (Levis et al, 2001) while, in both Ba/F3 cells 
expressing FLT3-ITD and primary AML blasts with FLT3-ITD mutations, AG1296 
treatment caused  reduction in the phosphorylation of signalling proteins downstream 
of FLT3, including STAT5 and ERK (Tse et al, 2002). The more water-soluble 
tricylic quinoxalines AGL2033 and AGL2043, similarly developed initially as PDGF-
R and KIT inhibitors also inhibit FLT3 and may be better candidates for clinical 
development (Gazit et al, 2003).  
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Indolinones 
A number of 3-substituted indolin-2-one compounds have been studied (Figure 3) 
with two agents SU5416 (Semaxinib) and SU11248 (Sunitinib) reaching early phase 
clinical trials. These compounds are relatively ‘broad spectrum’ tyrosine kinase 
inhibitors, developed primarily as angiogenesis inhibitors in view of their activity 
against the vascular endothelial growth factor (VEGF) receptor family, but 
subsequently found to potently inhibit FLT3, KIT and PDGF-Rβ. SU5416, SU5614 
and the ‘second generation’ indolinone compound SU11248 show selective cytotoxic 
effects in human leukaemic cell lines expressing activated FLT3 (Yee et al, 
2002;O'Farrell et al, 2003a). SU11248 in particular causes significant in vitro 
cytotoxicity at concentrations much lower than those required for maximal FLT3 
inhibition suggesting that its effects may arise from the simultaneous inhibition of 
several different kinases. 
 
SU5416 is relatively hydrophobic and highly protein bound in plasma. It was the first 
FLT3 inhibitor to reach the clinic: two separate phase 2 studies were conducted in 
AML based on its anti-angiogenic potential before its activity against FLT3 had been 
documented. In one study, 42 elderly or refractory AML patients were treated with 
twice-weekly intravenous infusions of SU5416 in four-week cycles (Fiedler et al, 
2003). One patient had a reduction in bone marrow blasts to <5% without neutrophil 
or platelet recovery while 7 other patients achieved a >50% reduction in bone marrow 
blasts, responses lasting between 1 and 5 months. Retrospective analysis showed that 
none of the responding patients harboured FLT3 mutations. Patients with high levels 
of bone marrow VEGF mRNA expression had a higher clinical response rate and 
reduction in marrow microvessel density than patients with low VEGF expression. In 
the second study, only 3 partial responses and 1 haematological improvement were 
documented amongst 33 AML and 22 MDS patients treated with SU5416 (Giles et al, 
2003). Results from a subsequent pharmacokinetic and pharmacodynamic study of 
SU5416 suggested that, due to its short half life and high protein binding, SU5416 
was likely to have inhibited FLT3 only briefly if at all in the above studies, possibly 
explaining the modest clinical efficacy (O'Farrell et al, 2004). This drug has now been 
withdrawn from further study. 
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Although also highly protein bound, SU11248 is orally-bioavailable and more 
hydrophilic than SU5416. In a single-dose phase 1 study, in vivo inhibition of FLT3 
phosphorylation was assessed at different time points in 29 patients (O'Farrell et al, 
2003b). FLT3 was inhibited in all 5 patients that harboured FLT3-activating 
mutations but only half of WT FLT3 cases. In a second phase 1 study, 16 patients 
with refractory AML were treated orally with SU11248 at a 50 or 75mg daily dose 
using a 4 weeks on, 1-2 weeks off schedule (Fiedler et al, 2005). Reductions in 
peripheral blood or bone marrow blasts were seen in 6 patients including all 4 with 
FLT3 mutations. Significant toxicity in the form of fatigue and hypertension, possibly 
due to the inhibition of multiple targets by this agent, was observed at the higher dose 
level. Although intermittent dosing has the potential to alleviate toxicity problems this 
may compromise target inhibition: in 4 cases rises in blast numbers were observed 
during the drug washout period. SU11248 is currently approved in the US for 
treatment of renal cell carcinoma and imatinib-refractory gastro-intestinal stromal 
tumours but, due to the pharmacokinetic difficulties in maintaining a FLT3-inhibitory 
concentration while avoiding toxicity, its future use in AML is uncertain. 
 
Indolocarbazoles 
Indolocarbazole FLT3 inhibitors (Figure 4) are alkaloid compounds that are derived 
from parent compounds of microbial origin. The two main agents in this class are 
CEP701 (Lestaurtinib) and PKC412, which are synthetically derived respectively 
from K-252a (the fermentation product of Nonomurea longicatena) and staurosporine.  
 
CEP701 was initially identified as an inhibitor of TrkA, a member of the nerve 
growth factor receptor subfamily, but was subsequently found to also inhibit FLT3. 
CEP701 is highly selective, potently inhibiting FLT3 and TrkA with respective IC50s 
of 3nM and 3.7nM but only inhibiting other type III RTKs such as KIT, PDGF-R 
and FMS at concentrations above 500nM. Although the drug is preferentially 
cytotoxic to FLT3-ITD expressing cell lines and primary AML samples it also 
displays activity against WT FLT3 (Levis et al, 2002;Brown et al, 2004;Knapper et 
al, 2006b). CEP701 prolongs survival in a mouse model of FLT3-ITD leukaemia 
(Levis et al, 2002).  
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CEP701 has good oral bioavailability and was well tolerated in two early phase 
clinical trials, the commonest reported toxicities being mild nausea and diarrhoea. In a 
US phase 1/2 trial of this agent, 14 heavily pretreated AML patients with FLT3 
activating mutations were treated with CEP701 60mg twice daily, with dose 
escalation to 80mg in 3 of the later patients after completion of 28 days of treatment 
(Smith et al, 2004). 5 patients showed a reduction in peripheral blood blasts and 1 of 
these patients showed a decrease in bone marrow blasts to <5%. All responses were 
short-lived, ranging from 2 weeks to 3 months in duration. In a second phase 2 trial of 
CEP701 monotherapy 29 previously-untreated elderly AML patients were treated at a 
twice-daily dose of 60mg for 8 weeks, with dose escalation to 80mg if well-tolerated 
(Knapper et al, 2006a). Clinical activity, manifest as transient reductions in bone 
marrow or peripheral blood blasts or longer periods of transfusion independence was 
seen in 3 of 5 evaluable patients with mutated FLT3 and 5 of 22 WT FLT3 patients. 
Both of these trials included detailed correlative laboratory analysis that confirmed 
that if a patient’s blasts were inherently sensitive to the FLT3 inhibitor as determined 
by in vitro cytotoxicty assay, and that the patient maintained a plasma CEP701 level 
sufficient for sustained inhibition of FLT3 to less than 10-15% of baseline activity, 
then a clinical response would be seen.  
 
PKC412 (N-benzoylstaurosporine) was originally developed as an inhibitor of protein 
kinase C, but has only relatively modest potency towards this enzyme. Like CEP701, 
PKC412 is a potent FLT3 inhibitor (IC50 approximately 10nM), but is slightly less 
selective than CEP701 amongst other kinases, inhibiting PDGF-R with an IC50 of 
80nM and KIT at doses above 500nM. PKC412 has been shown to inhibit FLT3 
phosphorylation in mutant and WT FLT3-transfected Ba/F3 cells. It inhibits the 
proliferation of FLT3-ITD and FLT3-TKD-expressing cell lines by causing cell cycle 
arrest and inducing apoptosis (Weisberg et al, 2002). Orally administered PKC412 
prolongs survival and prevents the development of splenomegaly in mice with lethal 
activated-FLT3-induced myeloproliferative syndrome (Kelly et al, 2002b;Weisberg et 
al, 2002). 
 
PKC412 also displays good oral bioavailability and, in a phase 2 study, was 
administered at a dose of 75mg three times daily to 20 patients with mutated FLT3 
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and either relapsed/refractory AML or high-risk myelodysplastic syndrome (Stone et 
al, 2005b). 14 patients showed a greater than 50% reduction in peripheral blood blast 
count, this being accompanied by a reduction in bone marrow blasts in 6 cases, with 
blasts falling to less than 5% (without blood count recovery) in 2 cases. Median 
clinical response duration was 13 weeks. Correlative studies showed that FLT3 
phosphorylation was inhibited in most responding patients. Interestingly, 
pharmacokinetic data from this trial showed that, following an initial peak, plasma 
concentrations of PKC412 fell by 70% at steady state, with levels of its active 
metabolite CGP52541 gradually rising and reaching a plateau after 28 days. 
CGP52541 has a broader spectrum of kinase inhibitory activity than PKC412 and is 
more cytotoxic to primary blast samples (Levis et al, 2006). It appears likely that 
much of PKC412’s clinical activity is actually attributable to CGP52541. 
 
MLN-518 
The piperazinyl quinazoline compound MLN-518 (Tandutinib, formerly known as 
CT-53518) (Figure 5) is another orally-bioavailable agent that, similar to the 
indolinone molecules, shows a relatively broad spectrum of kinase inhibition. Studies 
with a FLT3-ITD-expressing cell line yielded an IC50 of 30nM for FLT3 inhibition, 
but only 10nM for inhibition of proliferation, suggesting a possible multi-targeted 
effect. MLN-518 prolonged survival in a FLT3-ITD murine myeloproliferative model 
(Kelly et al, 2002c). Interestingly D835Y, the commonest FLT3-TKD mutation, 
confers in vitro resistance to this compound, which may limit its application (Clark et 
al, 2004). 
 
In a phase 1 study, 40 patients with AML or high risk myelodysplastic syndrome were 
treated with escalating doses of MLN-518 (DeAngelo et al, 2006). Dose limiting 
toxicity was muscular weakness or fatigue which occurred at doses above 525mg and 
was attributed to off-target binding of MLN-518 to a nicotinic receptor at the 
neuromuscular junction. Preliminary results from a phase 2 trial of FLT3-ITD positive 
patients treated with a twice-daily dose of 525mg demonstrated a clinical response in 
6 out of 15 evaluable patients with decreases in both peripheral blood and bone 
marrow blasts of 1-3 months duration (DeAngelo et al, 2004).  
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CHIR-258 
The recently-reported benzimidazole-quinolinone compound CHIR-258 (Figure 5) is 
another multi-targeted inhibitor with high in vitro potency against FLT3, KIT, VEGF 
1-3, PDGF-Rβ and fibroblast growth factor. It displays selective cytotoxicity in 
FLT3-ITD-dependent cell lines and prolongs survival in a murine FLT3-ITD model 
(Lopes de Menezes et al, 2005). Preliminary phase 1 data in 8 relapsed/refractory 
AML patients showed good tolerability (Morgan et al, 2005). The 1 patient that 
harboured a FLT3-ITD mutation had a near-complete clearance of blasts from both 
peripheral blood and bone marrow. Early phase clinical studies continue. 
 
Other compounds 
A number of other candidate molecules are at various stages of pre-clinical testing or 
early clinical development (Figure 5). Bay 43-9006 (Sorafenib), a urea derivative 
used in the treatment of renal cell carcinoma was initially developed to inhibit the 
serine threonine kinase Raf-1 but has recently been seen to inhibit class III receptor 
tyrosine kinases including FLT3, VEGF, KIT and PDGFR-β, and show selective 
cytotoxicity in FLT3-ITD expressing cell lines (Lierman et al, 2007). ABT-869, 
another urea-derivative displays multi-targeted receptor tyrosine kinase inhibition 
and, after evidence of in vitro cytotoxicity was seen in leukaemia cell lines and 
primary samples along with increased survival in a murine FLT3-ITD AML model, 
has entered phase 1 clinical development (Shankar et al, 2007). The in vitro efficacy 
of a third urea-derivative Ki23819 has previously been reported (Komeno et al, 2005) 
while a phase 1 trial of the compound KW-2449 is also underway. 
 
 
CHALLENGES IN THE FUTURE DEVELOPMENT OF FLT3 
INHIBITORS 
 
Based on the data from early phase clinical trials it appears that inhibition of FLT3 is, 
in general, safe and well tolerated. The levels of clinical response seen have been 
broadly similar and limited to transient clearances of blasts from the peripheral blood, 
reductions in bone marrow blasts or periods of transfusion independence that have 
lasted, at best, for only a few months. Even though the heavily pre-treated or elderly 
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populations studied to date have a notoriously poor prognosis, the results with FLT3-
inhibitor monotherapy fall some way short of those seen with imatinib in CML blast 
crisis. These trials and their correlative laboratory results have, however, provided 
good evidence linking sustained inhibition of FLT3 with clinical response while 
highlighting a number of issues that must be considered, both in the laboratory and in 
the future clinical development of these agents. 
 
On- target versus off- target activity 
As described above, FLT3-inhibitory compounds vary considerably in their potency 
and specificity. Although, at least initially, more is likely to be learned about the 
effects of FLT3 inhibition on AML pathophysiology by using ‘cleaner’ more FLT3-
selective agents, AML is a complex multigenetic disease and the simultaneous 
inhibition of other important tyrosine kinases including those that inhibit angiogenesis 
or even kinases from other families may be therapeutically advantageous. Broader 
spectrum kinase inhibition may come at a price, however, and there is some early 
clinical suggestion of increased toxicity with agents such as SU11248 and MLN-518. 
Concerns about the potentially potent myelosuppressive effects of dual FLT3 and KIT 
inhibition were somewhat alleviated by in vitro data showing that MLN-518, which 
inhibits both kinases with approximately equal potency had no effects on normal 
haematopoiesis in mice (Griswold et al, 2004).  
 
Protein binding and pharmacokinetics 
Pre-clinical data suggest that a cytotoxic effect is only seen in leukaemia cells when 
FLT3 phosphorylation is reduced in a sustained fashion to less than 10-15% of its 
baseline level (Levis et al, 2002). In clinical studies any benefit to the patient 
attributed to FLT3 inhibitors must be assessed in context of the degree and duration of 
target inhibition achieved. Inter-patient variations in drug metabolism and protein 
binding mean that FLT3-inhibitory activity cannot simply be determined by the 
measurement of plasma drug levels which frequently do not reflect the true level of 
unbound, active drug present. Direct assays of FLT3 inhibition are not possible in 
samples from patients with low circulating blasts numbers or when blasts are cleared 
in response to either the FLT3 inhibitor or accompanying cytotoxic chemotherapy. To 
circumvent these obstacles the Baltimore group have developed a ‘surrogate’ assay in 
which a FLT3-ITD-transfected leukaemia cell line (TF/ITD) is incubated with plasma 
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taken at appropriate time-points from the treated patient (Levis et al, 2006). The FLT3 
inhibitory activity in the patient plasma is then determined by lysis, 
immunoprecipitation and phospho-FLT3 immunoblotting of the treated TF/ITD cells. 
This ‘plasma inhibitory activity’ assay provides a means of assessing FLT3 inhibition 
over time which has been validated in patients receiving CEP701 and PKC412 (Smith 
et al, 2004;Levis et al, 2006;Knapper et al, 2006a). By judicious monitoring of 
plasma inhibitory levels in future studies it may be possible to tailor dosing in 
individual patients to ensure sustained FLT3-inhibitory levels in all cases. 
 
 
Resistance 
The clinical responses seen so far to FLT3 inhibitors have been almost exclusively 
short-lived, suggesting the presence of mechanisms by which leukaemic blasts may 
evade the effects of FLT3 inhibition. The acquisition of secondary tyrosine kinase 
domain point mutations that interfere with drug binding is a well-documented 
phenomenon in CML patients receiving therapy with imatinib (Wadleigh et al, 2005). 
Pre-clinical studies using AML cell lines have shown that small variations in the 
molecular structure of the FLT3 activation loop can greatly influence response to 
FLT3 inhibitors: cells that express different FLT3-TKD point mutations show 
distinctly different profiles of in vitro drug response (Grundler et al, 2003). Cools and 
colleagues described the results of an in vitro screen designed to discover mutations in 
the ATP-binding pocket of FLT3 that cause drug resistance: point mutations at 4 
different positions were identified that conferred varying degrees of resistance to 
PKC412, with variable cross-reactivity being seen with other inhibitors. One of these, 
the G697R mutation conferred high-level resistance to PKC412, SU5614 and K-252a 
as well as to six experimental molecules (Cools et al, 2004). In clinical trials of FLT3 
inhibitors to date there has been only one report of the acquisition of a secondary 
FLT3-TKD mutation: a patient that responded to PKC412 but became resistant to the 
drug after 280 days treatment was found to have developed a point mutation at one of 
the positions identified by Cools (N676K) that had not been present at diagnosis 
(Heidel et al, 2006).  
 
Increases in FLT3 expression during treatment represent another potential mechanism 
by which the efficacy of FLT3-inhibitors may be reduced. Laboratory assays 
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performed alongside the UK phase 2 study of CEP701 demonstrated increases in blast 
surface FLT3 expression during FLT3 inhibitor treatment in 13 out of 14 patients 
(Knapper et al, 2006a).  
 
Recent laboratory studies using primary AML blasts treated with CEP701 and 
PKC412 have suggested that FLT3 may not always provide the primary survival 
signal even in cases with high levels of activated FLT3 expression (Knapper et al, 
2006b). Furthermore, research using FLT3 inhibitor-resistant leukaemia cell lines, 
generated through prolonged co-culture with FLT3 inhibitors, has revealed that 
leukaemia cells may become FLT3 independent by activating compensatory 
signalling pathways (Piloto et al, 2007): in resistant cells, FLT3 itself could still be 
inhibited but several signalling pathways normally switched off by FLT3 inhibition, 
including PI-3 kinase/AKT and Ras/MEK/MAPK, remained activated. Newly-
acquired activating Ras mutations were found in 2 of the resistant cell lines, 
suggesting another means by which resistance may be acquired. This Ras-mediated 
resistance could be overcome by combining a FLT3 inhibitor with an inhibitor of PI3 
kinase or MEK, suggesting a future potential treatment strategy. 
 
Stem cell effects 
Pertinent to the design of clinical strategies to implement inhibition of FLT3, is the 
time sequence in which mutations are acquired in the process of leukaemogenesis. 
There are now data to support that FLT3 mutations frequently occur in leukaemia 
stem cells, although it appears that they can also represent late events arising in 
subclonal blast populations. Consistent with an ‘early hit’ hypothesis, FLT3-ITD 
mutations have recently been identified in purified CD34+/CD38- leukaemia-initiating 
stem cells, with these cells subsequently shown to successfully engraft FLT3-ITD 
AML in a NOD/SCID mouse model (Levis et al, 2005b). Analysis of paired patient 
samples has revealed that in 84% of patients with a FLT3-ITD at diagnosis, the 
mutation is also detectable at relapse (Shih et al, 2002). ITDs may sometimes, 
however, be acquired as late events: patients with myelodysplastic syndrome that lack 
a FLT3 ITD mutation at first diagnosis frequently develop one at the time of 
progression to AML, and AML patients who do not have FLT3 mutations at diagnosis 
may develop them at the time of relapse. In contrast, FLT3-TKD mutations seem to 
 17 
more usually represent ‘late hits’, being lost at relapse in more than half of cases (Shih 
et al, 2004). 
 
It has been hypothesised that stem-cell directed therapeutic effects could underlie 
delayed clinical responses reported in 2 CEP701-treated patients that peaked several 
weeks after the drug was withdrawn (Knapper et al, 2006a). A future strategy in 
which maintenance FLT3 inhibitor therapy is continued for a prolonged period after 
initial remission induction may have the potential to inhibit the regrowth of residual 
leukaemia stem cells. Such a strategy may be of lesser relevance in patients with 
FLT3-TKD mutations.  
 
Which patients should receive FLT3 inhibitors? 
A large body of pre-clinical evidence, assembled using both FLT3-expressing 
leukaemia cell lines and primary blast samples has shown that cells harbouring FLT3-
ITD mutations display a consistently greater sensitivity to the cytotoxic effects of 
FLT3 inhibitors than those that express only WT FLT3 (Levis et al, 2001;Brown et al, 
2004;Weisberg et al, 2002). Subsequent clinical studies have shown that the majority 
of patients with FLT3 ITD or TKD mutations who achieve a satisfactory plasma 
FLT3-inhibitory level will achieve some degree of clinical response (Smith et al, 
2004;Stone et al, 2005b). Patient numbers have so far being insufficient to 
observe any effect of ITD size on response rate, although there is some pre-
clinical evidence that blasts from cases with high mutant-to-wild-type FLT3 ratio 
are more sensitive to the in vitro effects of FLT3 inhibition (Brown et al, 2004). 
(Although sometimes seen,) Clinical responses to FLT3 inhibitors appear to be less 
freqeuent among FLT3 WT patients and appear to reflect the somewhat unpredictable 
degree of dependence that these leukaemias have on FLT3 signalling. At the time of 
writing, entry to the majority of ongoing FLT3 inhibitor trials is restricted to cases 
with mutant FLT3: other evolving molecular targets may ultimately have more 
relevance for the treatment of WT patients.  
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FLT3 INHIBITORS IN COMBINATION WITH CYTOTOXIC 
CHEMOTHERAPY 
 
Clinical responses to FLT3 inhibitor monotherapy have been relatively modest and in 
light of the accompanying rapid emergence of resistance seen in responding cases it 
appears likely that these drugs will only have a relatively limited future role as sole 
therapeutic agents. There is now a move towards employing FLT3 inhibitors in 
combination with conventional cytotoxic chemotherapy, this approach being 
supported by evidence from pre-clinical studies. In an in vitro model, CEP701 
demonstrated synergistic killing of FLT3-ITD-expressing leukaemia cell lines when 
combined in a time-sequence-specific manner with 4 different chemotherapeutic 
agents (Levis et al, 2004). Pre-treatment of cells with CEP701 before chemotherapy 
resulted in G1-phase cell cycle arrest and thus led to antagonism with the S-phase-
specific drug cytarabine. Synergistic cytotoxicity was seen, however, when the FLT3 
inhibitor was administered simultaneously-with or following chemotherapy. The 
authors concluded that CEP701 should be administered only after chemotherapy in 
future combination studies because the simultaneous administration of daunorubcin 
and CEP701 led to displacement of protein-bound daunorubicin into the serum 
resulting in potentially toxic anthracycline levels. SU11248 also showed additive or 
synergistic cytotoxic effects on leukaemia cell lines or primary blast samples when 
combined with cytarabine or daunorubicin (Yee et al, 2004). 
 
Clinical trials of both CEP701 and PKC412 used in combination with chemotherapy 
are now underway. In the first such study, PKC412 was combined simultaneously 
with standard cytarabine and daunorubicin-based induction and cytarabine-based 
consolidation chemotherapy in newly-diagnosed young adult AML patients 
irrespective of their FLT3 mutation status (Stone et al, 2005a). Initial 100mg twice 
daily dosing of PKC412 was associated with unacceptably high levels of emesis and 
biochemical liver derangement, perhaps consistent with the high anthracycline level-
related toxicity predicted by Levis’s pre-clinical CEP701 study (Levis et al, 2004). 
Better tolerability has since been seen at a modified dose of 50mg BD. Two separate 
phase 3 trials of CEP701 combined with chemotherapy are currently open. In a US-
based study which has now expanded internationally, AML patients with FLT3-
activating mutations in first relapse are randomised to receive salvage chemotherapy 
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alone or in combination with oral CEP701, which is introduced upon completion of 
each course of chemotherapy. Preliminary reports show this combination to be well-
tolerated with encouraging rates of clinical response that again correlate well with 
laboratory assays of FLT3 inhibition (Levis et al, 2005a). The UK-based MRC 
AML15 study for newly diagnosed adult patients below the age of 60 years has 
recently opened a randomisation that allocates half of patients identified on diagnostic 
screening to harbour a FLT3 mutation to receive CEP701 following each cycle of 
induction and consolidation chemotherapy. 
 
In the long term, simultaneous inhibition of multiple pathogenetic targets may be 
achievable by combining molecularly targeted therapeutic agents. A glimpse of the 
potential of such an approach was provided by a mouse model of FLT3-enhanced 
PML-RAR-positive APL in which a dramatic disease response was seen in mice 
treated with all-trans retinoic acid (ATRA) used in combination with the novel 
indolinone FLT3 inhibitor SU11657 (Sohal et al, 2003).  
 
 
NEW DIRECTIONS OF FLT3-DIRECTED THERAPY 
 
FLT3 inhibitors in acute lymphoblastic leukaemia 
FLT3 is expressed in nearly all cases of B-lineage ALL, with particularly high 
expression levels seen in infant ALL in association with rearrangements of the MLL 
gene at chromosome 11q23 (Armstrong et al, 2002). Activating mutations in the 
tyrosine kinase domain of FLT3 have been reported in up to 15% of these MLL-
rearranged ALL cases (Armstrong et al, 2004). In view of the extremely poor 
prognosis of infant ALL with a failure of standard therapy to cure the vast majority of 
patients, FLT3 inhibitors represent a potentially valuable new treatment strategy in 
this setting. Pre-clinical studies using CEP701 demonstrated selective in vitro 
cytotoxicity in ALL cell lines and in primary paediatric ALL blasts with high levels of 
FLT3 expression (Brown et al, 2005b), with evidence of sequence-dependent 
synergistic cytotoxic effects when combined with standard chemotherapeutic agents 
(Brown et al, 2005a). PKC412 is also differentially cytotoxic in vitro to ALL cells 
with MLL translocations and overexpression of WT or mutant FLT3 (Armstrong et 
al, 2003;Stam et al, 2005). In the US, Children’s Oncology Group trials of CEP701 in 
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combination with chemotherapy are planned in both relapsed FLT3-mutant AML and 
infants with MLL-rearranged ALL.       
 
Anti-FLT3 antibody therapy 
Antibodies targeted against FLT3 have recently been proposed as a potential means of 
avoiding some of the potential drawbacks of FLT3 inhibitors such as non-specific off-
target activity and acquired resistance. IMC-EB10 and IMC-NC7 are fully human 
monoclonal antibodies that are capable of blocking the binding of FLT3 ligand to 
FLT3. An inhibitory effect has been demonstrated on both ITD mutant and WT FLT3 
in AML cell lines and primary samples (Li et al, 2004;Piloto et al, 2005) while IMC-
EB10 in particular was able to initiate antibody-dependent cell mediated cytotoxicity 
in FLT3-expressing cells and increase survival in a murine model of FLT3-ITD 
leukaemia (Piloto et al, 2005). Although less in vitro cytotoxicity was seen against 
FLT3-overexpressing ALL cell lines, IMC-EB10 also significantly prolonged survival 
in a murine ALL model with most of this effect being mediated through natural killer 
cell activity (Piloto et al, 2006). Clinical trials of these antibodies are now being 
contemplated and there may be future potential for conjugation with cytotoxic agents. 
It remains to be seen whether their absolute specificity for FLT3 will ultimately be to 
their advantage or detriment.  
 
 
CONCLUSIONS 
 
The therapeutic inhibition of FLT3 retains the potential to profoundly improve AML 
treatment. Although relatively modest in depth and duration, the clinical responses 
seen in early phase clinical trials of small molecule FLT3 inhibitors, when considered 
alongside the results of correlative laboratory studies, confirm the clinical anti-
leukaemic efficacy of a strategy of sustained FLT3 inhibition in FLT3-dependent 
AML. There is now a strong body of pre-clinical evidence to support a synergistic 
relationship between FLT3 inhibitors and conventional cytotoxic agents if 
administered in the correct time sequence. Several trials of FLT3 inhibitors in 
combination with chemotherapy are now well underway, while trial protocols to 
assess the value of FLT3 inhibitors in leukaemia stem cell-directed post-
chemotherapy maintenance treatment are also anticipated. Ultimately, it is hoped that, 
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with increased knowledge of the complex molecular pathogenetic mechanisms 
underlying AML and improved diagnostic screening techniques, FLT3 inhibitors will 
be successfully utilised in combination with a range of other molecularly targeted 
agents tailored to effectively target the signalling pathways underlying the disease in 
individual patients while avoiding some of the toxicities associated with traditional 
chemotherapy.  
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Table 1: Direct inhibitors of FLT3 
 
 
Compound 
 
Chemical class 
FLT3 
IC50 
 
Other targets 
Clinical 
stage 
AG1295 Quinoxaline 1000nM PDGFR, KIT Lab only 
AG1296 Quinoxaline 1000nM PDGFR, KIT Lab only 
AGL2033 Quinoxaline 700nM PDGFR, KIT Lab only 
SU5416 (Sexamanib) 3-substituted indolinone 100nM KIT, VEGFR Phase 2 
SU5614 3-substituted indolinone 10nM KIT, FMS Lab only 
SU11248 (Sunitinib) 3-substituted indolinone 50nM KIT, PDGFR, VEGFR Phase 1 
CEP701 (Lestaurtinib) Indolocarbazole 3nM TRKA Phase 3 
PKC412 Indolocarbazole 10nM KIT Phase 3 
MLN-518 (Tandutinib) Piperazinyl quinazoline 30nM KIT, PDGFR Phase 2 
CHIR-258 Benzimidazole quinoline 1nM KIT, FMS, VEGFR, FGFR Phase 1 
BAY 43-9006 (Sorafenib) Bi-aryl urea <50nM B-RAF, PDGFR, VEGFR  Lab only 
ABT-869 Urea derivative 4nM KIT, KDR, PDGFR Phase 1 
Ki23819 Quinoline-urea 10nM n/a Lab only 
KW-2449 n/a 6nM KIT, Aurora kinase Phase 1 
 
FLT3 IC50 refers to the concentration required for 50% in vitro inhibition of FLT3 phosphorylation 
‘Other targets’ refers to other receptors known to be inhibited by the compound at similar 
concentrations to FLT3
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Table 2: FLT3 inhibitors in published clinical studies in AML 
 
Drug 
Trial 
stage 
 
Route and dose 
 
Patient eligibility 
n 
(AML) 
FLT3 
mutation 
 
Clinical response 
 
Adverse effects 
 
Reference 
SU5416 Phase 2 Intravenous 
145mg/m2 twice-
weekly 
Relapsed / refractory AML 
>60 yrs and unfit for intensive 
treatment 
42 
(42) 
7 ITD* BM blasts <5% without count 
recovery in 1 case  
>50% reduction in BM blasts in 
7 cases (no responses in ITD 
cases) 
Nausea, headache, 
bone pain 
(Fiedler et 
al, 2003) 
SU5416 Phase 2 Intravenous 
145mg/m2 twice-
weekly 
Relapsed / refractory AML 
High risk myelodysplastic 
syndrome 
55 
(33) 
Unknown BM blasts <5% without count 
recovery in 1 case 
>50% reduction in BM blasts in 
3 cases 
Headache, dyspnoea, 
fatigue, infusion 
reactions, thrombosis 
(Giles et al, 
2003) 
SU11248 Phase 1 Oral 50-350mg 
(Single dose only) 
AML (unrestricted) 29 
(29) 
3 ITD 
2 TKD 
Not applicable Nausea, diarrhoea (O'Farrell 
et al, 
2003b) 
CEP701 Phase 1/2 Oral 40-80mg BD Relapsed / refractory AML with 
FLT3-activating mutation 
 
17 
(17) 
16 ITD 
1 TKD 
BM blasts <5% without count 
recovery in 1 case 
Peripheral blood blast clearance 
in 4 cases 
Nausea, diarrhoea, 
fatigue 
(Smith et 
al, 2004) 
PKC412 Phase 2 Oral 75mg TDS Relapsed / refractory AML or high 
risk myelodysplastic syndrome 
with FLT3-activating mutation 
20 
(19) 
18 ITD 
2 TKD 
BM blasts <5% without count 
recovery in 3 cases  
>50% reduction in PB blasts in 
14 cases, >50% reduction in BM 
blasts in 6 cases 
Nausea, diarrhoea, 
fatigue, headache, 
oedema 
? pulmonary 
infiltrates 
(Stone et 
al, 2005b) 
SU11248 Phase 1 Oral 50-75mg 
daily 
Relapsed / refractory AML 
Unfit for intensive treatment 
15 
(15) 
2 ITD 
2 TKD 
Peripheral blast clearance or BM 
blast reduction in 4/4 FLT3 
mutant, 2/7 FLT3 WT cases 
Dose-limiting fatigue, 
hypertension at 75mg 
Oedema, fatigue 
(Fiedler et 
al, 2005) 
CEP701 Phase 2 Oral 60-80mg BD Newly-diagnosed AML >70yrs (or 
60-70yrs with comorbidity) 
 
29 
(29) 
2 ITD 
3 TKD 
Peripheral blood blast clearance 
or >50% BM blast reduction in 
3/5 FLT mutant, 5/22 FLT3 WT 
cases 
Nausea, diarrhoea, 
constipation, liver 
enzyme changes 
(Knapper et 
al, 2006a) 
MLN-518 Phase 1 Oral 50-700mg 
BD 
Relapsed / refractory AML 
Unfit for intensive treatment   
High risk MDS 
40 
(39) 
8 ITD 
1 TKD 
Peripheral blast clearance and 
reduction in BM blasts in 2 ITD 
cases (at doses above 525mg) 
Weakness, fatigue, 
nausea, diarrhoea, 
oedema 
(DeAngelo 
et al, 2006) 
ITD indicates FLT3 internal tandem duplication, TKD indicates FLT3 tyrosine kinase domain point mutation 
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*Retrospective FLT3 mutation screening in 35 patients only. No FLT3-TKD mutation analysis performed.
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